(Q24801183)

English

Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

0 references

author name string

Toralf Reimer

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Dirk Koczan

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Heiner Müller

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Klaus Friese

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Hans-Jürgen Thiesen

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Bernd Gerber

6

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

language of work or name

0 references

publication date

21 June 2002

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Breast Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

R9

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

7 April 2017

The Fas death factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

7 April 2017

Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Aging, immunity, and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Roles of Fas and Fas ligand during mammary gland remodeling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Absolute quantification of human chorionic gonadotropin-beta mRNA with TaqMan detection. 4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

The Fas counterattack: cancer as a site of immune privilege

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Human melanoma cells do not express Fas (Apo-1/CD95) ligand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Gene transfer of Fas ligand induces tumor regression in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 September 2017

Countering the 'counterattack' hypothesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

30 May 2018

Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway

1 reference

https://api.crossref.org/works/10.1186%2FBCR456

21 January 2018

Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system.

1 reference

https://api.crossref.org/works/10.1186%2FBCR456

21 January 2018

Regulation of Fas ligand expression by estradiol and progesterone in human endometrium

1 reference

https://api.crossref.org/works/10.1186%2FBCR456

21 January 2018

Estrogen receptor-mediated, nitric oxide-dependent modulation of the immunologic barrier function of the endothelium: regulation of fas ligand expression by estradiol

1 reference

https://api.crossref.org/works/10.1186%2FBCR456

21 January 2018

The role of the Fas/Fas ligand system in estrogen-induced thymic alteration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=125304

28 November 2018

CD95 ligand expression in dedifferentiated breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12223126

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic relevance of altered Fas (CD95)-system in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12223126

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12223126

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen

1 reference

https://pubmed.ncbi.nlm.nih.gov/12223126

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune privilege or inflammation? Insights into the Fas ligand enigma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12223126

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://pubmed.ncbi.nlm.nih.gov/12223126

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FasL:Fas ratio--a prognostic factor in breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/12223126

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24801183&oldid=2175262001"